Effects of Common Chemotherapy Drugs on the Human Gut Microbiome

Methodology

Abstract
The environment within the human gut contains many types of
microorganisms, called human gastrointestinal microbiota.
Throughout recent years, many studies have found a strong
correlation between the strengths and types of bacteria within the
human gut microbiome and the overall health of a person. More
specifically, studies have shown that the bacterial composition of an
individual’s gut microbiome has an impact on their physiological
response to chemotherapy. This year we have completed the first two
phases of our project. We have tested the effect of various
concentrations of various chemotherapy drugs on the growth of
human gut microbiota samples and identified and preserved samples
of interest exhibiting moderate growth and samples without treatment.
The next phase of the project is to perform DNA extraction upon the
preserved samples, and DNA sequence the samples to determine
which specific bacterial species were killed by each specific
chemotherapy drug. Further examination of these relationships could
be utilized to increase the efficacy and decrease the toxicity of
common chemotherapy drugs.

Conclusion
• From the results of our trials, the higher concentrations (60-80
microliters) of the chemotherapy drugs had clear effects on the
growth of human gut microbial communities and most likely affected
different bacterial species.
• We also have concluded that there may be a maximum chemotherapy
drug concentration level at which a difference in bacterial
composition is seen, as there was not a significant difference in the
results seen between the 80 and 100 microliter plates.

Future Experimentation
Figure 1. 96-Well Plates Set Up
•Send the preserved samples of interest for 16S rRNA sequencing
•Use the results to determine which bacterial species are present in each
moderate growth well sample and compare it to the bacterial species present
in the untreated sample

Hypothesis
When compared to the control group which consists of microbial
communities with no treatments, we expect that communities exposed to
chemotherapy drugs will have an alteration of the composition of the
bacterial species. Specifically, we expect that in high doses of
chemotherapy drugs certain bacterial species will be exterminated
resulting in a gradient of microbial growth. We expect that wells with
moderate microbial growth will have certain species of bacteria that are
affected by the different kinds of chemotherapy medication. The aim of
this project is to develop a relationship between specific chemotherapy
drugs and the specific bacterial species it targets.

•Examine which specific bacterial species were affected by each
chemotherapy drug
•Repeat the entire research study using a different donor’s gut microbiota
sample to ensure replicability and results

Figure 2. Anaerobic Hood Chamber

Introduction

Figure 3. Experimental Design

Results

•Repeat the entire research study with the addition of probiotics to determine
if they modulate the effect of the chemotherapy drugs upon the gut
microbiota sample
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Figure 1 Beta-diversity comparisons of the gut microbiomes of the fecal
samples collected before chemotherapy and after chemotherapy.
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